vs
Cooper Companies (The)(COO)与RxSight, Inc.(RXST)财务数据对比。点击上方公司名可切换其他公司
Cooper Companies (The)的季度营收约是RxSight, Inc.的32.7倍($1.1B vs $32.6M)。Cooper Companies (The)净利率更高(7.9% vs -28.1%,领先36.0%)。Cooper Companies (The)同比增速更快(4.6% vs -18.9%)。Cooper Companies (The)自由现金流更多($149.9M vs $-2.3M)。过去两年Cooper Companies (The)的营收复合增速更高(6.9% vs 5.1%)
CooperCompanies是总部位于美国加利福尼亚州圣拉蒙的全球医疗设备企业,旗下设有两大业务单元:主营隐形眼镜生产的库博光学,以及面向女性健康市场提供医疗设备、生育及基因组相关产品的库博外科。
RxSight是一家医疗科技企业,专注于研发和商业化适用于白内障及屈光晶状体置换手术的可调光人工晶状体产品,其核心产品支持术后通过专用照光设备调整晶状体度数,为全球眼科诊疗市场提供优化的术后视力解决方案。
COO vs RXST — 直观对比
营收规模更大
COO
是对方的32.7倍
$32.6M
营收增速更快
COO
高出23.5%
-18.9%
净利率更高
COO
高出36.0%
-28.1%
自由现金流更多
COO
多$152.2M
$-2.3M
两年增速更快
COO
近两年复合增速
5.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | ||
|---|---|---|
| 营收 | $1.1B | $32.6M |
| 净利润 | $84.6M | $-9.2M |
| 毛利率 | 61.1% | 77.5% |
| 营业利润率 | 13.2% | -34.8% |
| 净利率 | 7.9% | -28.1% |
| 营收同比 | 4.6% | -18.9% |
| 净利润同比 | -28.0% | -54.1% |
| 每股收益(稀释后) | $0.42 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
COO
RXST
| Q4 25 | $1.1B | $32.6M | ||
| Q3 25 | $1.1B | $30.3M | ||
| Q2 25 | $1.0B | $33.6M | ||
| Q1 25 | $964.7M | $37.9M | ||
| Q4 24 | $1.0B | $40.2M | ||
| Q3 24 | $1.0B | $35.3M | ||
| Q2 24 | $942.6M | $34.9M | ||
| Q1 24 | $931.6M | $29.5M |
净利润
COO
RXST
| Q4 25 | $84.6M | $-9.2M | ||
| Q3 25 | $98.3M | $-9.8M | ||
| Q2 25 | $87.7M | $-11.8M | ||
| Q1 25 | $104.3M | $-8.2M | ||
| Q4 24 | $117.5M | $-5.9M | ||
| Q3 24 | $104.7M | $-6.3M | ||
| Q2 24 | $88.9M | $-6.1M | ||
| Q1 24 | $81.2M | $-9.1M |
毛利率
COO
RXST
| Q4 25 | 61.1% | 77.5% | ||
| Q3 25 | 65.3% | 79.9% | ||
| Q2 25 | 67.8% | 74.9% | ||
| Q1 25 | 68.4% | 74.8% | ||
| Q4 24 | 66.5% | 71.6% | ||
| Q3 24 | 66.1% | 71.4% | ||
| Q2 24 | 67.0% | 69.5% | ||
| Q1 24 | 67.0% | 70.1% |
营业利润率
COO
RXST
| Q4 25 | 13.2% | -34.8% | ||
| Q3 25 | 16.6% | -40.1% | ||
| Q2 25 | 18.4% | -41.6% | ||
| Q1 25 | 18.9% | -28.2% | ||
| Q4 24 | 19.5% | -21.5% | ||
| Q3 24 | 19.2% | -26.1% | ||
| Q2 24 | 17.2% | -23.9% | ||
| Q1 24 | 16.4% | -36.2% |
净利率
COO
RXST
| Q4 25 | 7.9% | -28.1% | ||
| Q3 25 | 9.3% | -32.4% | ||
| Q2 25 | 8.7% | -35.0% | ||
| Q1 25 | 10.8% | -21.6% | ||
| Q4 24 | 11.5% | -14.8% | ||
| Q3 24 | 10.4% | -17.9% | ||
| Q2 24 | 9.4% | -17.4% | ||
| Q1 24 | 8.7% | -30.8% |
每股收益(稀释后)
COO
RXST
| Q4 25 | $0.42 | $-0.22 | ||
| Q3 25 | $0.49 | $-0.24 | ||
| Q2 25 | $0.44 | $-0.29 | ||
| Q1 25 | $0.52 | $-0.20 | ||
| Q4 24 | $0.59 | $-0.14 | ||
| Q3 24 | $0.52 | $-0.16 | ||
| Q2 24 | $0.44 | $-0.16 | ||
| Q1 24 | $0.41 | $-0.25 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $110.6M | $228.1M |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $8.2B | $275.7M |
| 总资产 | $12.4B | $311.8M |
| 负债/权益比越低杠杆越低 | 0.30× | — |
8季度趋势,按日历期对齐
现金及短期投资
COO
RXST
| Q4 25 | $110.6M | $228.1M | ||
| Q3 25 | $124.9M | $227.5M | ||
| Q2 25 | $116.2M | $227.5M | ||
| Q1 25 | $100.9M | $229.3M | ||
| Q4 24 | $107.6M | $237.2M | ||
| Q3 24 | $109.7M | $237.1M | ||
| Q2 24 | $112.4M | $233.3M | ||
| Q1 24 | $135.2M | $125.4M |
总债务
COO
RXST
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.6B | — | ||
| Q2 24 | $2.7B | — | ||
| Q1 24 | $2.7B | — |
股东权益
COO
RXST
| Q4 25 | $8.2B | $275.7M | ||
| Q3 25 | $8.4B | $276.0M | ||
| Q2 25 | $8.3B | $278.0M | ||
| Q1 25 | $8.1B | $279.3M | ||
| Q4 24 | $8.1B | $281.2M | ||
| Q3 24 | $7.9B | $277.3M | ||
| Q2 24 | $7.8B | $275.2M | ||
| Q1 24 | $7.7B | $163.9M |
总资产
COO
RXST
| Q4 25 | $12.4B | $311.8M | ||
| Q3 25 | $12.4B | $308.5M | ||
| Q2 25 | $12.4B | $309.0M | ||
| Q1 25 | $12.2B | $313.0M | ||
| Q4 24 | $12.3B | $318.6M | ||
| Q3 24 | $12.1B | $310.5M | ||
| Q2 24 | $12.0B | $305.5M | ||
| Q1 24 | $12.0B | $183.2M |
负债/权益比
COO
RXST
| Q4 25 | 0.30× | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.30× | — | ||
| Q1 25 | 0.31× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $247.9M | $-1.1M |
| 自由现金流经营现金流 - 资本支出 | $149.9M | $-2.3M |
| 自由现金流率自由现金流/营收 | 14.1% | -6.9% |
| 资本支出强度资本支出/营收 | 9.2% | 3.5% |
| 现金转化率经营现金流/净利润 | 2.93× | — |
| 过去12个月自由现金流最近4个季度 | $433.7M | $-19.3M |
8季度趋势,按日历期对齐
经营现金流
COO
RXST
| Q4 25 | $247.9M | $-1.1M | ||
| Q3 25 | $261.4M | $-1.2M | ||
| Q2 25 | $96.2M | $-4.4M | ||
| Q1 25 | $190.6M | $-8.8M | ||
| Q4 24 | $268.1M | $-4.3M | ||
| Q3 24 | $207.5M | $650.0K | ||
| Q2 24 | $111.0M | $-4.0M | ||
| Q1 24 | $122.7M | $-9.3M |
自由现金流
COO
RXST
| Q4 25 | $149.9M | $-2.3M | ||
| Q3 25 | $164.5M | $-1.8M | ||
| Q2 25 | $18.1M | $-5.9M | ||
| Q1 25 | $101.2M | $-9.4M | ||
| Q4 24 | $128.1M | $-5.1M | ||
| Q3 24 | $118.5M | $-453.0K | ||
| Q2 24 | $36.9M | $-5.5M | ||
| Q1 24 | $4.6M | $-11.3M |
自由现金流率
COO
RXST
| Q4 25 | 14.1% | -6.9% | ||
| Q3 25 | 15.5% | -5.8% | ||
| Q2 25 | 1.8% | -17.6% | ||
| Q1 25 | 10.5% | -24.8% | ||
| Q4 24 | 12.6% | -12.7% | ||
| Q3 24 | 11.8% | -1.3% | ||
| Q2 24 | 3.9% | -15.9% | ||
| Q1 24 | 0.5% | -38.2% |
资本支出强度
COO
RXST
| Q4 25 | 9.2% | 3.5% | ||
| Q3 25 | 9.1% | 1.9% | ||
| Q2 25 | 7.8% | 4.6% | ||
| Q1 25 | 9.3% | 1.5% | ||
| Q4 24 | 13.7% | 2.1% | ||
| Q3 24 | 8.9% | 3.1% | ||
| Q2 24 | 7.9% | 4.4% | ||
| Q1 24 | 12.7% | 6.7% |
现金转化率
COO
RXST
| Q4 25 | 2.93× | — | ||
| Q3 25 | 2.66× | — | ||
| Q2 25 | 1.10× | — | ||
| Q1 25 | 1.83× | — | ||
| Q4 24 | 2.28× | — | ||
| Q3 24 | 1.98× | — | ||
| Q2 24 | 1.25× | — | ||
| Q1 24 | 1.51× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
COO
| Sphere Other | $365.0M | 34% |
| Toric And Multifocal | $344.7M | 32% |
| Office And Surgical | $214.5M | 20% |
| Fertility | $140.9M | 13% |
RXST
| Rxlal | $28.2M | 86% |
| LDD | $3.0M | 9% |
| Service Warranty Service Contracts And Accessories | $1.5M | 4% |